卵巢癌化疗新进展与治疗Thestateoftheartinchemotherapyforovariancancers.pptVIP

  • 2
  • 0
  • 约1.4千字
  • 约 88页
  • 2020-12-13 发布于广东
  • 举报

卵巢癌化疗新进展与治疗Thestateoftheartinchemotherapyforovariancancers.ppt

;卵巢癌化疗新进展和治疗Thestateoftheartinchemotherapyforovariancancers;Women ;上海市居民卵巢癌、宫颈癌、宫体癌发病率(1974-2000,SCDC);;;;;;;卵巢癌化疗新进展和治疗Thestateoftheartinchemotherapyforovariancancers;;准确全面分期依据手术探查和 病理组织学、细胞学检查 根据腹腔内转移灶的大小对III期再分为IIIa、IIIb、IIIc 腹膜后淋巴结转移影响分期 肝表面和肝实质转移分属III期和IV期;卵巢癌化疗新进展和治疗Thestateoftheartinchemotherapyforovariancancers;卵巢癌化疗新进展和治疗Thestateoftheartinchemotherapyforovariancancers;;;;;;;;;;;;;;IV → IP;;;;3周疗→周疗;;;;;;;;;卵巢癌化疗新进展和治疗Thestateoftheartinchemotherapyforovariancancers;;;;二线化疗的目标;对铂类敏感的卵巢癌;;Pfisterer et al. J Clin Oncol 2006;24(29):4699-4707.;;铂类敏感的复发卵巢癌患者 健择?联合卡铂方案显著延长PFS,提高缓解率,且未降低生活质量1 健择?联合卡铂快速缓解症状,并明显改善生活质量2;;铂类耐药复发性卵巢癌治疗模式:;对铂类耐药卵巢癌;有效率 随机临床试验,0 – 6个月;有效率 随机临床试验, 6个月;;R;;铂类耐药复发性卵巢癌治疗模式:;;;;R;R;;Results: OR 16% vs. 18% (Gem), OR duration 18 vs. 17 (Gem) weeks ; n.s. QoL advantage for caelyx in 2 of 4 time points (p 0.05);铂类耐药复发性卵巢癌治疗模式:;;二线治疗;卵巢癌化疗新进展和治疗Thestateoftheartinchemotherapyforovariancancers;Maintenance(维持) Prolonged administration of treatment 延长治疗 Treatment until progression 治疗至进展 Consolidation(巩固) A defined therapy following a response to initial treatment 首次治疗有效后,接着同样的治疗;;;;卵巢癌化疗新进展和治疗Thestateoftheartinchemotherapyforovariancancers;;;;;卵巢癌诊断:细胞减灭术 化疗 随访: Ca125 ? 立即化疗? 出现症状或体征后再化疗?;卵巢癌化疗新进展和治疗Thestateoftheartinchemotherapyforovariancancers;;;;;;

文档评论(0)

1亿VIP精品文档

相关文档